Related Experiment Video

Updated: May 29, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma

Megumi Fujita1, Tatsurou Yagami, Miki Fujio

  • 1Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo, Japan.

Cancer Letters
|September 10, 2011
PubMed

Insights

Troglitazone (TGZ) shows cytotoxicity against renal cell carcinoma (RCC) by activating the p38 MAPK pathway, independent of PPARγ. This activation also leads to G2/M cell cycle arrest, offering potential therapeutic insights.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are explored for cancer chemoprevention and therapy.
  • Renal cell carcinoma (RCC) remains a significant oncological challenge requiring novel therapeutic strategies.

Purpose of the Study:

  • To investigate the cytotoxic effects of troglitazone (TGZ) on human RCC cell lines.
  • To elucidate the mechanisms underlying TGZ cytotoxicity, focusing on PPARγ dependency and the p38 mitogen-activated protein kinase (MAPK) pathway.

Main Methods:

  • Treatment of 786-O, Caki-2, and ACHN RCC cell lines with TGZ.
  • Assessment of apoptosis induction and cytotoxicity.
  • Analysis of PPARγ and p38 MAPK pathway activation.
  • Evaluation of cell cycle progression, specifically G2/M arrest.

Main Results:

  • Troglitazone (TGZ) induced apoptosis and cytotoxicity in RCC cells in a PPARγ-independent manner.
  • TGZ activated the p38 MAPK pathway, which was integral to its cytotoxic effects.
  • Activation of the p38 MAPK pathway by TGZ resulted in G2/M cell cycle arrest.

Conclusions:

  • Troglitazone exerts cytotoxicity in renal cell carcinoma through a mechanism independent of PPARγ.
  • The p38 MAPK pathway plays a critical role in mediating TGZ-induced apoptosis and G2/M cell cycle arrest in RCC.
  • These findings suggest TGZ as a potential agent for RCC therapy, highlighting the p38 MAPK pathway as a therapeutic target.

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...